Inventor · disambiguated record
Christine Fritsch
Also filed as: FRITSCH CHRISTINE
6 granted patents·16 pending applications·14 citations·filing 2008–2021
72Inventor score
Files withNOVARTIS AG10FRITSCH CHRISTINE4GARCIA-ECHEVERRIA CARLOS3BRACHMANN SASKIA MARIA2DI TOMASO EMMANUELLE1
Top patents by PatentIndex Score
22 records- 0183US9370508B2Imidazoquinolines as dual lipid kinase and mTOR inhibitorsGARCIA-ECHEVERRIA CARLOS·Filed 2008·Granted Jun 21, 2016·13 cites·1 claims
- 0262US9675595B2Synergistic combinations of PI3K- and MEK-inhibitorsFRITSCH CHRISTINE·Filed 2012·Granted Jun 13, 2017·1 cites·2 claims
- 0360US2021196696A1Dosage regimen for an alpha-isoform selective phosphatidylinositol 3-kinase inhibitorNOVARTIS AG·Filed 2020·Application pending·0 cites
- 0457US2020022967A1Use of 2-carboxamide cycloamino urea derivatives in the treatment of EGFR dependent diseases or diseases that have acquired resistance to agents that target EGFR family membersNOVARTIS AG·Filed 2019·Application pending·0 cites
- 0556US2011105521A1Combination of (a) a phosphoinositide 3-kinase inhibitor and (b) a modulator of ras/raf/mek pathwayNOVARTIS AG·Filed 2009·Application pending·0 cites
- 0655US2018325883A1Use of 2-carboxamide cycloamino urea derivatives in the treatment of EGFR dependent diseases or diseases that have acquired resistance to agents that target EGFR family membersNOVARTIS AG·Filed 2018·Application pending·0 cites
- 0754US9241939B2Combination of (a) a phosphoinositide 3-kinase inhibitor and (b) a modulator of RAS/RAF/MEK pathwayGARCIA-ECHEVERRIA CARLOS·Filed 2014·Granted Jan 26, 2016·0 cites·4 claims
- 0853US10434092B2Dosage regimen for an alpha-isoform selective phosphatidylinositol 3-kinase inhibitorNOVARTIS AG·Filed 2017·Granted Oct 8, 2019·0 cites·5 claims
- 0953US2020069670A1Dosage regimen for an alpha-isoform selective phosphatidylinositol 3-kinase inhibitorNOVARTIS AG·Filed 2019·Application pending·0 cites
- 1052US12226405B2Compounds and compositions for inhibiting the activity of HIF2-alpha and their methods of useNOVARTIS AG·Filed 2021·Granted Feb 18, 2025·0 cites·30 claims
- 1151US2018085362A1Combination of phosphatidylinositol-3-kinase (pi3k) inhibitor and a mtor inhibitorNOVARTIS AG·Filed 2017·Application pending·0 cites
- 1248US2013209461A1Use of 2-carboxamide cycloamino urea derivatives in the treatment of EGFR dependent diseases or diseases that have acquired resistance to agents that target EGFR family membersBRACHMANN SASKIA MARIA·Filed 2011·Application pending·0 cites
- 1348US2017000778A1Dosage regimen for an alpha-isoform selective phosphatidylinositol 3-kinase inhibitorDI TOMASO EMMANUELLE·Filed 2014·Application pending·0 cites
- 1447US2014057904A1Combination of (a) a phosphoinositide 3-kinase inhibitor and (b) a modulator of RAS/RAF/MEK pathwayGARCIA-ECHEVERRIA CARLOS·Filed 2013·Application pending·0 cites
- 1544US2014275089A12-Carboxamide Cycloamino Urea Derivatives in Combination with HSP90 Inhibitors for the Treatment of Proliferative DiseasesNOVARTIS AG·Filed 2012·Application pending·0 cites
- 1644US2015250778A1Use of 2-carboxamide cycloamino urea derivatives in the treatment of EGFR dependent diseases or diseases that have acquired resistance to agents that target EGFR family membersBRACHMANN SASKIA MARIA·Filed 2015·Application pending·0 cites
- 1743US2014066474A1Combination of phosphatidylinositol-3-kinase (pi3k) inhibitor and a mtor inhibitorFRITSCH CHRISTINE·Filed 2012·Application pending·0 cites
- 1842US2017095463A1Combination of phosphatidylinositol-3-kinase (pi3k) inhibitor and a mtor inhibitorFRITSCH CHRISTINE·Filed 2016·Application pending·0 cites
- 1941US9795596B2Pharmaceutical diagnosticFURET PASCAL·Filed 2013·Granted Oct 24, 2017·0 cites·2 claims
- 2039US2016095842A1Combination therapy containing a pi3k-alpha inhibitor and fgfr kinase inhibitor for treating cancerFRITSCH CHRISTINE·Filed 2014·Application pending·0 cites
- 2137US2018280370A1Dosage regimen for a phosphatidylinositol 3-kinase inhibitorNOVARTIS AG·Filed 2016·Application pending·0 cites
- 2237US2016199365A12-Carboxamide Cycloamino Urea Derivatives in Combination with HSP90 Inhibitors for the Treatment of Proliferative DiseasesHUANG XIZHONG·Filed 2016·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Christine Fritsch files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →